Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Germany

Launch follows authorization; AMNOG early benefit assessment determines added benefit and frames subsequent price negotiation.

EMA / EC

G-BA / IQWiG

GKV-SV

G-BA

4 decision nodes18 cited sources

For education only — not regulatory, pricing or legal advice.